{"id":847,"date":"2010-09-07T14:27:23","date_gmt":"2010-09-07T18:27:23","guid":{"rendered":"http:\/\/sciencebusiness.technewslit.com\/?p=847"},"modified":"2010-09-07T14:27:23","modified_gmt":"2010-09-07T18:27:23","slug":"phase-2-clinical-trial-planned-for-depression-drug","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=847","title":{"rendered":"Phase 2 Clinical Trial Planned for Depression Drug"},"content":{"rendered":"<p><a href=\"http:\/\/www.rexahn.com\/cms\">Rexahn Pharmaceuticals Inc.<\/a>, a clinical stage pharmaceutical company in Rockville, Maryland, submitted today a Phase 2b protocol to the U.S. Food and Drug Administration for the clinical study of Serdaxin, a drug that treats major depressive disorder.<\/p>\n<p>The company says Serdaxin may work as an enhancer of <a href=\"http:\/\/www.medterms.com\/script\/main\/art.asp?articlekey=5468\">serotonin<\/a> and <a href=\"http:\/\/www.medterms.com\/script\/main\/art.asp?articlekey=14345\">dopamine<\/a> in the brain. In Rexahn&#8217;s proof of concept study, Serdaxin showed numerical differences versus a placebo for response and remission rates, as well as statistical significance in the severe patient population versus a placebo. The trial also demonstrated Serdaxin to be safe and well tolerated without the appearance of serious side effects that are commonly linked to currently marketed antidepressants.<\/p>\n<p>This clinical study will assess Serdaxin&#8217;s efficacy as a treatment for major depressive disorder in approximately 300 subjects.\u00a0 The planned double blind, randomized, placebo-controlled trial will be conducted at multiple sites in the U.S. and will measure the change from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) as the primary measure of efficacy.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Rexahn Pharmaceuticals Inc., a clinical stage pharmaceutical company in Rockville, Maryland, submitted today a Phase 2b protocol to the U.S. Food and Drug Administration for the clinical study of Serdaxin, a drug that treats major depressive disorder. The company says Serdaxin may work as an enhancer of serotonin and dopamine in the brain. In Rexahn&#8217;s [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[15,5],"tags":[28,22,27],"class_list":["post-847","post","type-post","status-publish","format-standard","hentry","category-products","category-regulations","tag-clinical-trials","tag-fda","tag-pharmaceuticals"],"_links":{"self":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/847","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=847"}],"version-history":[{"count":4,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/847\/revisions"}],"predecessor-version":[{"id":851,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/847\/revisions\/851"}],"wp:attachment":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=847"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=847"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=847"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}